Vivo Capital’s acquisition of Angiotech

O’Melveny advised Vivo Capital as the leader of an investment syndicate in the investment syndicate’s definitive agreement to acquire Canadian medical device maker Angiotech Pharmaceuticals.

Vivo Capital, LLC is a private equity and venture capital firm specializing in incubation, seed, startup, mezzanine, and PIPE investments in private and public companies. The company, led by Frank F. C. Kung, Hwachie Lee, Edgar G. Engleman, Albert Cha and Chen-Ming Yu is based in Palo Alto (CA).

Under the terms of the agreement, the investment syndicate will acquire 100 percent of the shares of Angiotech. The deal is expected to close in the first quarter of 2017.

The O’Melveny team was led by partner Paul Scrivano (Picture) and associates Noah Kornblith, Amanda Bradley, Martha Todd, and Jake Leraul.

Involved fees earner: Paul Scrivano – O’Melveny & Myers LLP; Noah Kornblith – O’Melveny & Myers LLP; Amanda Bradley – O’Melveny & Myers LLP; Martha Todd – O’Melveny & Myers LLP; Jake Leraul – O’Melveny & Myers LLP;

Law Firms: O’Melveny & Myers LLP;

Clients: Vivo Capital;


Author: Ambrogio Visconti